LianBio (LIAN)
0.32
0.00 (0.31%)
At close: Jan 16, 2025, 9:00 PM
0.00
-100.00%
After-hours Dec 31, 1969, 07:00 PM EST
undefined% (undefined)
| Bid | n/a |
| Market Cap | 34.47M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.82 |
| PE Ratio (ttm) | -0.39 |
| Forward PE | n/a |
| Analyst | Sell |
| Ask | n/a |
| Volume | 2,485,055 |
| Avg. Volume (20D) | 959,835 |
| Open | 0.31 |
| Previous Close | 0.32 |
| Day's Range | 0.31 - 0.32 |
| 52-Week Range | 0.24 - 4.99 |
| Beta | undefined |
About LIAN
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 1, 2021
Employees 163
Stock Exchange NASDAQ
Ticker Symbol LIAN
Website https://www.lianbio.com
Analyst Forecast
According to 3 analyst ratings, the average rating for LIAN stock is "Sell." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 33.33%
Hold 33.33%
Sell 33.33%
11 months ago
+18.81%
LianBio shares are trading higher after the compan...
Unlock content with
Pro Subscription